Organon & Co. reported GAAP net income of $164 million for the quarter ended September 30, 2026, up from $160 million in 2025, while adjusted net income fell to $256 million from $263 million and adjusted EBITDA declined to $502 million from $518 million.
OGN · Organon & Co.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Organon agreed to sell all outstanding shares to Sun Pharma for $14.00 per share in cash, with closing expected by early 2027. Worldwide sales were $1.6 billion for the three months ended September 30, 2026, down 2%.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Arcoxia | $69M | FY2026 Q3 | -2.8% |
|
|
|||
| Atozet | $85M | FY2026 Q3 | -10.5% |
|
|
|||
| Cozaar/Hyzaar | $51M | FY2026 Q3 | -7.3% |
|
|
|||
| Dulera | $35M | FY2026 Q3 | +2.9% |
|
|
|||
| Emgality | $59M | FY2026 Q3 | +15.7% |
|
|
|||
| Follistim AQ | $67M | FY2026 Q3 | +4.7% |
|
|
|||
| Hadlima | $75M | FY2026 Q3 | -6.3% |
|
|
|||
| Marvelon/Mercilon | $28M | FY2026 Q3 | -9.7% |
|
|
|||
| Nasonex | $65M | FY2026 Q3 | +8.3% |
|
|
|||
| Nexplanon/Implanon NXT | $200M | FY2026 Q3 | -10.3% |
|
|
|||
| NuvaRing | $25M | FY2026 Q3 | -3.8% |
|
|
|||
| Renflexis | $67M | FY2026 Q3 | -4.3% |
|
|
|||
| Singulair | $45M | FY2026 Q3 | -15.1% |
|
|
|||
| Vtama | $42M | FY2026 Q3 | +23.5% |
|
|
|||
| Bildyos/Bilprevda | $19M | the three months ended June 30, 2026 filing | — |
| Brenzys | $14M | the three months ended June 30, 2026 filing | — |
| Favorable foreign exchange impact on worldwide sales | $42M | the three months ended June 30, 2026 filing | — |
| Ontruzant | $6M | the three months ended June 30, 2026 filing | — |
| Zetia/Vytorin | $118M | the three months ended June 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Drug Manufacturers - General — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
OGN
this stock
Organon & Co.
|
$3.65B | +93.9% | -2.9% | 18.1 | 7.5% |
|
LLY
ELI LILLY & Co
|
$1.33T | +31.7% | +44.7% | 45.9 | 0.8% |
|
JNJ
Johnson & Johnson
|
$670.92B | +34.7% | +6.0% | 42.4 | 0.7% |
|
ABBV
AbbVie Inc.
|
$517.59B | +28.2% | +8.6% | 50.4 | 0.9% |
|
MRK
Merck & Co., Inc.
|
$353.44B | +36.2% | +1.3% | 147.8 | 1.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Oct 30, 2026
- This year
- 27
Organon & Co. reported GAAP net income of $164 million for the quarter ended September 30, 2026, up from $160 million in 2025, while adjusted net income fell to $256 million from $263 million and adjusted EBITDA declined to $502 million from $518 million.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| OGN | +0.1% | +1.0% | +4.1% | +0.4% | +93.9% |
| SPY | -2.3% | -4.8% | -2.9% | -3.1% | +7.4% |
| vs SPY | +2.4% | +5.8% | +7.1% | +3.5% | +86.5% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.